Ventyx Biosciences

Yahoo Finance • 3 days ago

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress

On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines(NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade. What happened According to a SEC filing dated February 13,... Full story

Yahoo Finance • 3 days ago

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million

On February 13, 2026, Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics(NASDAQ:APGE), an estimated $3.87 million trade based on quarterly average pricing. What happened According to an SEC filing dated... Full story

Yahoo Finance • 7 days ago

Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.

Wall Street tends to latch onto exciting stories. Sometimes, however, investors are so nearsighted that they forget to consider the long-term picture. That's what could be taking place with Eli Lilly(NYSE: LLY) today. It's a good thing tha... Full story

Yahoo Finance • 12 days ago

Halper Sadeh LLC is Investigating STEL, CWBC, SKYT, VTYX on Behalf of Shareholders

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 14 days ago

Halper Sadeh LLC is Investigating STEL, CLBK, NFBK, VTYX on Behalf of Shareholders

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 14 days ago

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—SKYT, GORO, STEL, and VTYX

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in th... Full story

Yahoo Finance • 3 months ago

Ventyx Provides Clinical and Corporate Updates

Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in prep... Full story

Yahoo Finance • 3 months ago

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediate... Full story

Yahoo Finance • 3 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediate... Full story

Yahoo Finance • 3 months ago

Ventyx Biosciences GAAP EPS of -$0.32

* Ventyx Biosciences press release [https://seekingalpha.com/pr/20297770-ventyx-biosciences-reports-third-quarter-2025-financial-results-and-highlights-recent] (VTYX [https://seekingalpha.com/symbol/VTYX]): Q3 GAAP EPS of -$0.32. * Cas... Full story

Yahoo Finance • 3 months ago

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker trial support the potential use of... Full story

Yahoo Finance • 4 months ago

VTYX Surges On Phase 2 Data: VTX3232 Cuts Inflammation, Lifts Stock By 83% After Hours

(RTTNews) - Shares of Ventyx Biosciences Inc. (VTYX) skyrocketed over 83% in after-hours trading on Wednesday after the company announced positive results from its Phase 2 study of VTX3232, an oral, once-daily NLRP3 inhibitor. The trial ta... Full story

Yahoo Finance • 4 months ago

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6... Full story

Yahoo Finance • 6 months ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflamma... Full story

Yahoo Finance • 8 months ago

Ventyx reports positive Phase 2a results for Parkinson's drug

SAN DIEGO - Ventyx Biosciences, Inc. (NASDAQ:VTYX), a clinical-stage biotech company with a market capitalization of $181 million, announced Tuesday that its Phase 2a study of VTX3232, an oral NLRP3 inhibitor for early-stage Parkinson’s di... Full story

Yahoo Finance • 8 months ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neurodegenerative d... Full story

Yahoo Finance • 12 months ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform developme... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases wit... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases wit... Full story

Yahoo Finance • 2 years ago

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16 Efficacy results did not meet the internal target to support further development of VTX9... Full story